Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Typhoid conjugate vaccine - International Vaccine Institute/Incepta/SK Bioscience/PT Biofarma

Next Previous
Drug Profile

Typhoid conjugate vaccine - International Vaccine Institute/Incepta/SK Bioscience/PT Biofarma

Alternative Names: NBP-618; SKYTyphoid®; Typhoid-vaccine-Vi-DT-conjugate; Vi-DT; Vi-DT conjugated typhoid vaccine; Vi-DT Typhoid Conjugate Vaccine

Latest Information Update: 13 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator International Vaccine Institute
  • Developer Incepta Vaccine; International Vaccine Institute; PT Bio Farma; SK Bioscience
  • Class Bacterial vaccines; Conjugate vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Typhoid

Most Recent Events

  • 13 Jan 2025 No development reported - Phase-III for Typhoid (In adolescents, In children, In infants, Prevention, In adults) in Indonesia (IM)
  • 13 Jan 2025 No development reported - Phase-III for Typhoid (In adolescents, In children, In infants, Prevention, In adults) in Philippines (IM)
  • 30 Dec 2024 PT Bio Farma completes a phase II/III trial in Typhoid (Prevention, In children, In adolescents, In adults, In infants) in Indonesia (IM) (NCT04741828)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top